腹膜透析患者结核性腹膜炎治疗与结局的系统综述
结果显示腹膜透析患者结核性腹膜炎虽不常见但结局差,ANZDATA病例的拔管和永久转血透率(82%)高于病例研究(23%)和队列研究(20%),而全因死亡率在病例研究(33%)和队列研究(26%)中高于ANZDATA病例(6%)。
要点
- 腹膜透析患者结核性腹膜炎虽不常见,但与不良结局相关。
- ANZDATA登记病例拔管和永久转血透率(82%)高于文献病例(23%)和队列研究(20%)。
- 全因死亡率在病例研究(33%)和队列研究(26%)中高于ANZDATA登记病例(6%)。
核心结论
- 腹膜透析患者结核性腹膜炎不常见且与不良结局相关,需前瞻性研究评估感染后保留腹膜透析导管对患者结局的影响。
研究设计与样本
- 系统综述检索Medline、Scopus、Embase、ClinicalTrials.gov、Cochrane CENTRAL和Google Scholar自建库至2022年6月的文献,纳入描述患者特征、初始抗结核治疗和结局的研究。
- 文献检索识别70项病例研究(151例)和8项队列研究(97例)。
主要发现
- ANZDATA登记病例的拔管和永久转血透率(82%)在数值上高于病例研究(23%)和队列研究(20%)。
- 全因死亡率在病例研究(33%)和队列研究(26%)中高于ANZDATA登记病例(6%)。
临床怎么用
- 临床应认识到腹膜透析患者结核性腹膜炎虽不常见但结局差,需关注拔管和转血透风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Peritoneal dialysis (PD)-associated peritonitis due to tuberculosis (TB) is associated with poor outcomes and optimal treatment strategies for this condition remain unknown. Our study aimed to: (i) systematically review the published literature on peritonitis caused by Mycobacterium tuberculosis in patients on PD and (ii) review cases of peritonitis due to M tuberculosis in patients on PD reported in Australia and New Zealand to determine the epidemiology, management strategies, and outcomes of this condition. METHODS: A literature search of Medline, Scopus, Embase, ClinicalTrials.gov, Cochrane CENTRAL Register of Controlled Trials and Google Scholar for articles published from inception date to June 2022 was conducted. To be eligible, articles had to describe patient characteristics, initial anti-TB therapy, and treatment outcomes in all patients on PD with peritonitis caused by M tuberculosis. Data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry of patients on PD who developed peritonitis due to M tuberculosis between September 2001 and December 2020 were included and analyzed. RESULTS: The systematic literature review identified 70 case studies (151 patients) and 8 cohort studies (97 patients), whereas the ANZDATA Registry identified 17 cases of peritonitis due to M tuberculosis. Overall, in patients diagnosed with peritonitis due to M tuberculosis, the rates of PD catheter removal and permanent transfer to hemodialysis (HD) were numerically higher in the ANZDATA Registry cases (82%) than in the case studies (23%) and cohort studies (20%). Observed all-cause mortality rates were also higher as observed in the case studies (33%) and cohort studies (26%) than in the ANZDATA Registry cases (6%). CONCLUSION: Tuberculous peritonitis is uncommon in patients on PD and is associated with poor outcomes. Prospective studies are warranted to study the effect of retaining PD catheters after M tuberculosis infection on patient outcomes.
引用
- Ling CW, Sud K, Castelino RL, et al. Systematic Review on Treatment and Outcomes of Tuberculous Peritonitis in Patients on Peritoneal Dialysis. Kidney Int Rep. 2023. PMID: 38344729. doi:10.1016/j.ekir.2023.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。